ID 110178
Title Transcription
メタボリック ショウコウグン ニオケル コウケツアツ ノ カンリ
Title Alternative
Contrrol of hypertension in metabolic syndrome
Author
Nakaya, Yutaka Department of Nutrition and Metabolism, Institute of Health Biosciences, The University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Harada, Nagakatsu Department of Nutrition and Metabolism, Institute of Health Biosciences, The University of Tokushima Graduate School KAKEN Search Researchers
Mawatari, Kazuaki Department of Nutrition and Metabolism, Institute of Health Biosciences, The University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Takahashi, Akira Department of Nutrition and Metabolism, Institute of Health Biosciences, The University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Hosaka, Toshio Department of Nutrition and Metabolism, Institute of Health Biosciences, The University of Tokushima Graduate School
Keywords
hypertension
diabetes mellitus
metabolic syndrome
angiotensin
insulin resistance
Content Type
Journal Article
Description
Metabolic syndrome includes abdominal obesity, hyperlipidemia, diabetes, and hypertension. All, but hypertension, are obviously related to metabolism. However, hypertension might result from, at least in part, abdominal obesity, because adipose tissue produces bioactive mediators (adipocytokines)which increase blood pressure. In treatment of hypertension, we should concern insulin resistance, which is a major risk factor of cardiovascular events. Angiotensin converting enzyme inhibitor is known to improve insulin resistance, but results of angiotensin receptor blocker in animal studies are controversial. In clinical trial, there are many established data that ARBs prevent new onset of diabetes mellitus, suggesting that this agent also has a beneficial effect on glucose metabolism. Short acting Ca-antagonists, such as nifedipine, decrease insulin sensitivity, but long-acting Ca-antagonists increase it. βblockers decrease insulin sensitivity but those with α-blocking action improve insulin resistance. Recent study, ARB is more potent to reduce cardiovascular risk in those with obesity than in those with normal body weight, suggesting some drugs are more effective in metabolic syndrome. Thus, when we chose antihypertensive drugs in treating patients with metabolic syndrome, we have to choose proper drugs in addition to modify life-style.
Journal Title
四国医学雑誌
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
63
Issue
3-4
Start Page
97
End Page
100
Sort Key
97
Published Date
2007-08-25
EDB ID
FullText File
language
jpn
TextVersion
Publisher
departments
Medical Sciences